Copyright: ©Author(s) 2026.
World J Cardiol. Jul 26, 2026; 18(7): 121472
Published online Jul 26, 2026. doi: 10.4330/wjc.v18.i7.121472
Published online Jul 26, 2026. doi: 10.4330/wjc.v18.i7.121472
Table 1 Tabulated representation of baseline characteristics of included randomized controlled trials
| Ref. | Type of study | Location | Total study population | Ivabradine | Placebo | Duration of study |
| Čiburienė et al[13], 2023 | Randomized open label trial | Lithuania | 48 | 21 | 27 | 6 months |
| Rizk et al[14], 2025 | Tripple blind randomized controlled trial | Spain | 107 | 51 | 56 | 12 months |
| Vasyuk et al[15], 2017 | Open labelled randomized controlled trial | Russia | 55 | 23 | 32 | 12 months |
- Citation: Sohail R, Khattak R, Shah HH, Khan Z, Jawed S, Wasim AU, Akram B, Patel R, Patel S, Alam M, Chaudhry S, Mehdi S, Patel V, Singh M. Preventing anthracycline-induced cardiotoxicity with ivabradine: A systematic review and meta-analysis. World J Cardiol 2026; 18(7): 121472
- URL: https://www.wjgnet.com/1949-8462/full/v18/i7/121472.htm
- DOI: https://dx.doi.org/10.4330/wjc.v18.i7.121472